Literature DB >> 16085741

Malaria in the post-genomics era: light at the end of the tunnel or just another train?

D L Gardiner1, J S McCarthy, K R Trenholme.   

Abstract

Malaria remains the third leading cause of death attributable to an infectious disease worldwide, with an estimated death toll of over 2 million per year, predominately in sub-Saharan Africa. The first serious attempt to eradicate this disease was unsuccessful, and 50 years later in 1998 a second programme coined "roll back malaria" was started. While this programme is at present unlikely to reach its stated aims, the completion of the genome sequencing projects on the human host, the mosquito vector, and the malaria parasite offers new hope. It is probable that the burden of disease caused by the most malignant form of the parasite Plasmodium falciparum can be, if not eliminated, then effectively suppressed within a generation through new and novel treatments aimed at all three arms of malaria control.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16085741      PMCID: PMC1743328          DOI: 10.1136/pgmj.2004.030304

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  35 in total

1.  Malaria transmission and vector control.

Authors:  B M Greenwood
Journal:  Parasitol Today       Date:  1997-03

2.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

Authors:  K A Bojang; P J Milligan; M Pinder; L Vigneron; A Alloueche; K E Kester; W R Ballou; D J Conway; W H Reece; P Gothard; L Yamuah; M Delchambre; G Voss; B M Greenwood; A Hill; K P McAdam; N Tornieporth; J D Cohen; T Doherty
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

Review 3.  Molecular entomology and prospects for malaria control.

Authors:  F H Collins; L Kamau; H A Ranson; J M Vulule
Journal:  Bull World Health Organ       Date:  2003-11-17       Impact factor: 9.408

4.  Transgenic anopheline mosquitoes impaired in transmission of a malaria parasite.

Authors:  Junitsu Ito; Anil Ghosh; Luciano A Moreira; Ernst A Wimmer; Marcelo Jacobs-Lorena
Journal:  Nature       Date:  2002-05-23       Impact factor: 49.962

Review 5.  Conquering the intolerable burden of malaria: what's new, what's needed: a summary.

Authors:  Joel G Breman; Martin S Alilio; Anne Mills
Journal:  Am J Trop Med Hyg       Date:  2004-08       Impact factor: 2.345

Review 6.  Malaria vaccine developments.

Authors:  Vasee S Moorthy; Michael F Good; Adrian V S Hill
Journal:  Lancet       Date:  2004-01-10       Impact factor: 79.321

Review 7.  The global distribution and population at risk of malaria: past, present, and future.

Authors:  Simon I Hay; Carlos A Guerra; Andrew J Tatem; Abdisalan M Noor; Robert W Snow
Journal:  Lancet Infect Dis       Date:  2004-06       Impact factor: 25.071

8.  Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

Authors:  Vasee S Moorthy; Egeruan B Imoukhuede; Sheila Keating; Margaret Pinder; Daniel Webster; Michael A Skinner; Sarah C Gilbert; Gijs Walraven; Adrian V S Hill
Journal:  J Infect Dis       Date:  2004-05-24       Impact factor: 5.226

9.  Efficacy trial of malaria vaccine SPf66 in Gambian infants.

Authors:  U D'Alessandro; A Leach; C J Drakeley; S Bennett; B O Olaleye; G W Fegan; M Jawara; P Langerock; M O George; G A Targett
Journal:  Lancet       Date:  1995-08-19       Impact factor: 79.321

Review 10.  The Anopheles gambiae genome: next steps for malaria vector control.

Authors:  Yeya T Touré; Ayoade M J Oduola; Carlos M Morel
Journal:  Trends Parasitol       Date:  2004-03
View more
  1 in total

1.  Expression, purification, and characterization of the immunological response to a 40-kilodalton Plasmodium vivax tryptophan-rich antigen.

Authors:  Asim A Siddiqui; Hema Bora; Neeru Singh; Aditya P Dash; Yagya D Sharma
Journal:  Infect Immun       Date:  2008-03-24       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.